{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:03:30Z","timestamp":1784811810592,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T00:00:00Z","timestamp":1632182400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1136923"],"award-info":[{"award-number":["1136923"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001102","name":"Cancer Council NSW","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001102","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp;amp; Perspec"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The standard approach for dose individualization of chemotherapy in the oncology setting has long been based on body surface area (BSA) as a measure of body size. However, for many anticancer drugs, administration of dosages based on BSA may result in some patients receiving supratherapeutic or subtherapeutic concentrations due to substantial interindividual pharmacokinetic variability. Therapeutic drug monitoring (TDM)\u2013guided dosing aims to ensure that the patient's serum drug concentration is in a target range which has been shown to produce optimal clinical outcomes. The management of several malignancies is now moving away from using traditional intravenous chemotherapy to longer\u2010term treatment with targeted molecular therapies. These targeted anticancer drugs are currently dosed based on a fixed dose for all patients. The pharmacokinetic characteristics of most of these drugs (e.g., tyrosine\u2010kinase inhibitors) support implementation of individualized dosing via TDM. However, prior to adopting TDM\u2013guided dosing in oncology settings, the economic efficiency and value for money of introducing TDM interventions should be critically and systematically examined along with the impacts on patient care and outcomes. Yet, current evidence in this area is limited, and more generally, there is lack of methodological guidance on how to identify, estimate and value clinical and cost information necessary to conduct economic evaluations of TDM interventions. In this paper, we propose a coherent framework for conducting economic evaluation of TDM interventions in oncology settings and discuss some practical challenges of conducting economic evaluations of TDM.<\/jats:p>","DOI":"10.1002\/prp2.862","type":"journal-article","created":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T05:15:21Z","timestamp":1632201321000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A framework for economic evaluation of therapeutic drug monitoring\u2014guided dosing in oncology"],"prefix":"10.1002","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8878-0317","authenticated-orcid":false,"given":"Daniel","family":"Erku","sequence":"first","affiliation":[{"name":"Centre for Applied Health Economics Griffith University Nathan Queensland Australia"},{"name":"Menzies Health Institute Queensland Griffith University Gold Coast Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8009","authenticated-orcid":false,"given":"Jennifer","family":"Schneider","sequence":"additional","affiliation":[{"name":"School of Medicine and Public Health The University of Newcastle Callaghan New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-642X","authenticated-orcid":false,"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[{"name":"Centre for Applied Health Economics Griffith University Nathan Queensland Australia"},{"name":"Menzies Health Institute Queensland Griffith University Gold Coast Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03014-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-019-02704-2"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.5362"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2009.24.1.1"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00177"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.013"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.014"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2599-1"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.194"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14494"},{"key":"e_1_2_10_13_1","volume-title":"Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (Version 5.0)","author":"Pharmaceutical Benefits Advisory Committee","year":"2016"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00045.x"},{"key":"e_1_2_10_15_1","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond MF","year":"2015"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_10_17_1","unstructured":"National Cancer Institute.Common terminology criteria for adverse events (CTCAE) version 5.0.2017. Accessed October 1 2020.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50"},{"key":"e_1_2_10_18_1","unstructured":"EORTIC Qulaity of Life Working Group.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ\u2010C30). Accessed October 1 2020.https:\/\/qol.eortc.org\/questionnaire\/eortc\u2010qlq\u2010c30\/"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-013-0033-x"},{"key":"e_1_2_10_20_1","volume-title":"Guide to the Methods of Technology Appraisal","author":"National Institute for Health and Clinical Excellence","year":"2013"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826040-00003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258\u2010019\u201000467\u20106"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-0753-5_901"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1217-y"},{"key":"e_1_2_10_25_1","volume-title":"The Pharmaceutical Benefits Scheme","author":"Australian Government Department of Health","year":"2017"},{"key":"e_1_2_10_26_1","unstructured":"Pathway of Research to Evaluation of Dose\u2010Individualised Cancer Therapy (PREDICT) Program.The University of Newcastle.2018. Accessed November 2 2020.https:\/\/www.newcastle.edu.au\/research\/centre\/clinical\u2010pharmacology\/research\/predict"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d1548"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.862","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.862","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:37:59Z","timestamp":1784810279000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,21]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/prp2.862"],"URL":"https:\/\/doi.org\/10.1002\/prp2.862","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,21]]},"assertion":[{"value":"2021-07-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00862"}}